The primary focus of the Stanford ACTG is the development and evaluation of antiretroviral drug combinations and strategies for the use of highly active antiretroviral therapy in the long-term treatment of HIV infection. The laboratory efforts to evaluate surrogate markers for virus replication included development of plasma HIV RNA PCR and the initial application of quantitative measures of viral replication to clinical trials of antiretroviral drugs and immunotherapeutics. Clinical trial strategies in combination therapies included the leadership of studies of sequential and combination nucleoside analog therapies, early studies combining antiretroviral agents and vaccines and immunotherapeutics and the first trial to use evidence of drug resistance to trigger changes in antiretroviral regimens. In the last few years the laboratory and clinical focus of the Stanford ACTG has concentrated on the use of multiple, sequential combinations in therapeutic strategies that include comparison of two, three and four drug regimens and the use of ultrasensitive HIV RNA and genotypic susceptibility testing to direct the optimal use of highly active therapies.
The aim of these studies is to provide rational and effective new combinations in an optimal sequence for initial and subsequent treatment of HIV infection and to develop salvage therapies in highly drug experienced subjects. In recent years their efforts have increased in outreach and in methods of measuring compliance as well. They intend to continue to bring innovative clinical science to bear on infection but also must continue the patient focus on bringing more women and more minorities into the program as the epidemic changes its pattern making these groups the major target of infection. Because of Stanford and this group's involvement with the major supplier of primary HIV care to Santa Clara and San Mateo Counties, they expect to be able to enter more patients into opportunistic infection protocols as well as the ALLRT and woman's health studies. The unit has advanced virology and pharmacology technology laboratories.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI027666-17S1
Application #
6697012
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Matula, Margaret A
Project Start
1986-06-30
Project End
2004-12-31
Budget Start
2003-01-01
Budget End
2003-12-31
Support Year
17
Fiscal Year
2003
Total Cost
$58,244
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61

Showing the most recent 10 out of 111 publications